688076.SH
Sinopep-Allsino Bio Pharmaceutical Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 27.55
+1.36%Year over year
Reported trailing growth
- Revenue
- +5.2%
- EBITDA
- —
- EBIT
- -30.0%
- EPS
- -39.4%
- Free cash flow
- +38.5%
- Operating cash flow
- +46.4%
Forward estimates
Based on analyst estimates
- Revenue
- +1.2%
- EBITDA
- +24.2%
- EPS
- -27.5%
Three-year CAGR
- Revenue
- +44.0%
- EBITDA
- +47.1%
- EBIT
- +49.0%
- Net income
- +37.4%
- EPS
- +20.9%
- Free cash flow
- +0.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026